Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review

Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review

Li Zhang, Zhongxiao Wu Department of Dermatology, Ningbo No 6 Hospital, Ningbo, 315040, People’s Republic of ChinaCorrespondence: Zhongxiao Wu, Email wzx2033@163.comAbstract: Sintilimab is a recombinant fully human anti-programmed cell death protein 1 (PD-1) monoclonal antibody that blocks the inter...

Full description

Bibliographic Details
Main Authors: Zhang L, Wu Z
Format: Article
Language:English
Published: Dove Medical Press 2023-02-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
adverse events
gastric malignancy
sintilimab
programmed death-1 inhibitor
toxic epidermal necrolysis
antitumor necrosis factor-α
Online Access:https://www.dovepress.com/adalimumab-for-sintilimab-induced-toxic-epidermal-necrolysis-in-a-pati-peer-reviewed-fulltext-article-CCID

Internet

https://www.dovepress.com/adalimumab-for-sintilimab-induced-toxic-epidermal-necrolysis-in-a-pati-peer-reviewed-fulltext-article-CCID

Similar Items